COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma.

Cancers (Basel) · 2026 · PMC12939694 · PMID 41749920

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

High-level treatment-related adverse event management showed a trend toward improved treatment adherence (HR: 0.74; [0.49–1.14]), which was statistically significant for pyrexia.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.